Poxel SAS

185 articles about Poxel SAS

• Poxel Announces its Participation at Upcoming October 2023 Investor Conferences

  10/12/2023

  POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced that it will participate at two upcoming investor conferences.

• Poxel Announces its Participation at Upcoming Scientific Conference

  10/2/2023

  POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced that it will participate at the upcoming 12th International Meeting on AMPK on October 4th, 2023.

• Poxel Reports Financial Results for First Half 2023 and Provides a Corporate Update

  9/26/2023

  POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced its financial results for the period ended June 30, 2023 and provided a corporate update.

• Poxel to Report 2023 First Half-Year Results and host a video conference on September 26, 2023

  9/7/2023

  POXEL SA announced that it will report its financial results for the Half-Year 2023 on Tuesday, September 26, 2023.

• Poxel Announces Upcoming Participation at the H.C. Wainwright 2nd Annual Kidney Conference

  7/18/2023

  POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced its participation at the upcoming H.C.

• Poxel, winner of the 2023 edition of the I-nov contest

  7/5/2023

  POXEL SA announces to be the winner of the 2023 edition of the I-nov contest for its program in adrenoleukodystrophy, a rare neurometabolic disease, for which there is currently no treatment.

• Poxel Announces the Approval of a Prospectus for the Listing of New Shares on Euronext Paris

  6/30/2023

  POXEL SA announces that the Autorité des Marchés Financiers approved a Prospectus for the admission of new shares of the Company that have been and may further be issued upon exercise of bonds redeemable in shares or bonds redeemable in new or existing ordinary shares that already been issued or that may further be issued pursuant to the financing agreements entered into with IRIS, respectively on August 5, 2022 and March 22, 2023.

• Poxel Announces Results from June 21, 2023 Ordinary Annual and Extraordinary General Meeting

  6/23/2023

  POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announces that it held its ordinary annual and extraordinary general meeting of shareholders on June 21, 2023.

• Poxel Announces its Participation at Patient Association Conferences in Adrenoleukodystrophy

  6/15/2023

  POXEL SA announced its participation at the ULF Scientific Symposium and Family Conference on June 23rd and 24th in Itasca, Illinois, USA.

• Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023

  5/16/2023

  POXEL SA announces the publication of the meeting notice for the Annual General Meeting, which will be held on June 21, 2023 at 9 am CEST at the Mercure Hotel, Lyon Centre Saxe Lafayette, 29 rue de Bonnel, 69003 LYON, France.

• Poxel Announces TWYMEEG® (Imeglimin) Fiscal Year 2022 Sales

  5/15/2023

  Regulatory News: POXEL SA announced TWYMEEG® Fiscal Year and fourth quarter 2022 results, as recently published by Sumitomo Pharma, its partner commercializing TWYMEEG in Japan.

• Poxel Announces Upcoming Participation at the JMP Securities Life Science Conference

  5/11/2023

  POXEL SA announced its participation at the JMP Securities Life Science Conference, to be held in New York, NY, Monday, May 15, and Tuesday, May 16, 2023.

• Poxel Announces Multiple TWYMEEG® (Imeglimin) Abstracts Accepted for Oral Presentation

  4/20/2023

  POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL),announced today that nine abstracts based on Imeglimin Phase 2b and Phase 3 clinical trials have been accepted for oral presentations at the 66th Annual Meeting of the Japanese Diabetes Society (JDS), held in Kagoshima, Japan, May 11-13, 2023.

• Poxel Reports Financial Results for Full Year 2022 and Provides Corporate Update

  3/23/2023

  POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced its results for the year ended December 31, 2022 and provided a corporate update.

• Poxel Announces Cash Runway Extended Through Q2 2025 Based upon Debt Restructuring Agreement and New Equity-linked Financing Facility

  3/23/2023

  POXEL SA announced that is has finalized agreements with its lenders to restructure its existing debt obligations and a new equity-linked financing with IRIS with an initial drawdown of EUR 3.5 million.

• Poxel will Report its 2022 Full Year Results on March 23, 2023

  3/22/2023

  POXEL SA announced it will report its 2022 Full year results on March 23, 2023, before market opening.

• Poxel to Report its 2022 Full Year Results by the End of March 2023

  3/22/2023

  POXEL SA announced that it will report its 2022 full year results by the end of March 2023.

• Poxel Announces Upcoming Participation at Evercore ISI’s NASH Renaissance Event

  3/15/2023

  POXEL SA announced its participation at the NASH Renaissance virtual event hosted by Evercore ISI on Thursday, March 30, 2023.

• Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology

  3/7/2023

  POXEL SA, clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced publication in Journal of Hepatology of positive results for DESTINY-1, a 36-week dose-ranging Phase 2 trial.

• Poxel Announces Publication in Kidney International of PXL770 Preclinical Results in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  3/1/2023

  POXEL SA announced the publication of preclinical results in autosomal dominant polycystic kidney disease for PXL770, a novel, first-in-class direct adenosine monophosphate-activated protein kinase activator.